Pacific Biosciences of California (PACB) Competitors

Harvard Bioscience (NASDAQ:HBIO) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.

Which has more risk & volatility, HBIO or PACB?

Harvard Bioscience has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Which has higher earnings & valuation, HBIO or PACB?

Harvard Bioscience has higher earnings, but lower revenue than Pacific Biosciences of California. Harvard Bioscience is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$112.25M	0.65	-$3.41M	-$0.33	-5.06
Pacific Biosciences of California	$200.52M	1.97	-$306.73M	-$1.46	-0.99

Is HBIO or PACB more profitable?

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -227.69%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-14.57%	-4.64%	-2.40%
Pacific Biosciences of California	-227.69%	-42.71%	-15.38%

Do institutionals and insiders believe in HBIO or PACB?

80.9% of Harvard Bioscience shares are held by institutional investors. 9.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer HBIO or PACB?

Pacific Biosciences of California received 82 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 72.02% of users gave Harvard Bioscience an outperform vote while only 66.67% of users gave Pacific Biosciences of California an outperform vote.

Company	Underperform	Outperform
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%
Pacific Biosciences of California	Outperform Votes 450 66.67%	Underperform Votes 225 33.33%

Do analysts prefer HBIO or PACB?

Pacific Biosciences of California has a consensus price target of $2.89, suggesting a potential upside of 100.44%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pacific Biosciences of California	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media refer more to HBIO or PACB?

In the previous week, Pacific Biosciences of California had 5 more articles in the media than Harvard Bioscience. MarketBeat recorded 6 mentions for Pacific Biosciences of California and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.47 beat Pacific Biosciences of California's score of -0.25 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harvard Bioscience and Pacific Biosciences of California tied by winning 9 of the 18 factors compared between the two stocks.